Τίτλος:
Comparative analysis of peripheral and localised cytokine secretion in
glioblastoma patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Malignant gliomas are the most common primary brain tumours
of both children and adults. The unique aspects of their biology and
anatomic site render them refractory to conventional therapeutic
strategies such as surgery and chemotherapy. Significant attention has
been given, recently, to immunotherapy which, although promising in
preclinical studios, has not yet enhanced the survival of patients with
glioblastomas. Methods: To further understand the immunobiology of
glioblastomas in clinical settings, we examined the secretion of four
main cytokines in the peripheral blood and in primary cell cultures of
33 human glioblastoma patients. An ELISPOT methodology was used for the
first time to examine Th1, and Th2 cytokine secretion from both
peripheral lymphocytes and glioma tumour cells. Results: Th1 cytokines
(tumour necrosis factor (TNF-alpha), interferon (IFN-7) were markedly
reduced compared to control levels (P = 0.01 and P < 0.001,
respectively), whereas in contrast, Th2 (interleukin (IL)-4 and IL-10)
were strongly expressed in both peripheral lymphocytes and glioma cell
cultures (P = 0.05 and P < 0.001, respectively). Conclusion: This
pattern indicates an ‘immunosuppressive status’ in glioblastomas which
is related to their origination and the evasion of glioma cells from
immune surveillance and could account for the failure of immunotherapy
in such tumours. Furthermore, ELISPOT methodology can be used for
monitoring of cytokine secretion from tumour cells, in addition to the
well-established peripheral cytokine secretion. (c) 2007 Elsevier Ltd.
All rights reserved.
Συγγραφείς:
Zisakis, Athanasios
Piperi, Christina
Themistocleous, Marios S.
and Korkolopoulou, Penelope
Boviatsis, Efstathios I.
Sakas,
Darnianos E.
Patsouris, EfStratios
Lea, Robert W. and
Kalofoutis, Anastasios
Εκδότης:
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Λέξεις-κλειδιά:
cytokine; glioblastoma; primary glioma cell line; immunotherapy
DOI:
10.1016/j.cyto.2007.05.012
